Welcome to the MATTO New Ventures Showcase – an opportunity to meet with spin-off companies from universities and hospitals that are seeking expansion investment.

The 18 presenting companies have already raised almost $20 million and are looking for additional capital for further product research, final product development and for market launch. From new materials and software to new medical devices and drug candidates, the companies represent the broad range of research and innovation that is occurring here.

This event is also an opportunity for you to show your support of the spin-off companies that each year are created by the inventor entrepreneurs at our research institutions and which form a strong core to our innovation economy. These companies are seeking funding but they are also looking for advice and access to new networks - come and help them on this quest.

We hope you enjoy today's program. Please stay for this evening’s closing networking reception that will enable you to meet individually with our researchers and entrepreneurs.

We would like to express our sincere gratitude to our conference supporters listed below for their financial assistance as well as to our organizing committee Todd Keiller (WPI), Michal Preminger (Harvard), Susan Daudelin (UMass Boston) and Julia Goldberg (MTTC) for their help in putting together today’s program.

Vinit Nijhawan
President, MATTO

Dr. Abigail A. Barrow,
Director, Massachusetts Technology Transfer Center

Supporters

Greenberg Traurig
Silicon Valley Bank
Lando & Anastasi
The University of Massachusetts Club
## CONFERENCE AGENDA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 – 1:30</td>
<td>Registration, Dessert Bar, and Networking</td>
<td>Boston Room</td>
</tr>
<tr>
<td>1:30 – 1:45</td>
<td>Welcome</td>
<td>Boston Room</td>
</tr>
<tr>
<td>1:45 – 2:45</td>
<td>Company Pitch Presentations - Session One</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Life Sciences</strong></td>
<td>Lowell Room</td>
</tr>
<tr>
<td></td>
<td>PanTher Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CryptoMedix, LLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NeuroFieldz Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Constant Therapy, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VitaThreads, LLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Physical Sciences</strong></td>
<td>Boston Room</td>
</tr>
<tr>
<td></td>
<td>Weave Visual Analytics, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Battery Resourcers LLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corsair Innovations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SLIPS Technologies, Inc.</td>
<td></td>
</tr>
<tr>
<td>2:45 – 3:15</td>
<td>Coffee Break</td>
<td>Boston Room</td>
</tr>
<tr>
<td>3:15 – 4:30</td>
<td>Company Pitch Presentations - Session Two</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Life Sciences</strong></td>
<td>Lowell Room</td>
</tr>
<tr>
<td></td>
<td>Mellitus, LLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LayerBio, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Standard Molecular, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CaroGen Corporation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chestnut Pharmaceuticals Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Physical Sciences</strong></td>
<td>Boston Room</td>
</tr>
<tr>
<td></td>
<td>StreetScan Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sonation, Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MazeFire LLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Felsuma LLC</td>
<td></td>
</tr>
<tr>
<td>4:30 – 6:30</td>
<td>Networking Reception</td>
<td>Boston Room</td>
</tr>
</tbody>
</table>
Company Profiles

Battery Resourcers LLC

Contact person: Eric Gratz, Chief Technology Officer
Phone: 206 - 948 6325
Email: egratz@gmail.com
Technology from: Worcester Polytechnic Institute

Company Overview
Battery Resourcers LLC goal is to improve the recycling rates and efficiency of lithium ion batteries as well as lower the cost of cathode materials for Li-ion batteries. By lowering the cost of cathode materials, Battery Resourcers has the potential to make green technologies more viable by making energy storage more affordable. Battery Resourcers LLC will license and develop a novel method of recovering active cathode materials from spent lithium ion batteries that does not require any sorting and can handle any lithium ion battery regardless of size, shape or chemistry. From the spent batteries, Battery Resourcers recovers like new $\text{LiNi}_{1/3}\text{Mn}_{1/3}\text{Co}_{1/3}\text{O}_2$ (NMC). The recycling technology was developed in Assistant Professor Yan Wang’s (also cofounder and Chief Academic Advisor) electrochemistry lab at Worcester Polytechnic Institute (WPI). Battery Resourcers LLC also founded by Eric Gratz Ph.D (CTO) who has been working on lithium ion battery recycling for three years and Diran Apelian (Board Director) who also serves as the Alcoa-Howmet Professor of Mechanical Engineering at WPI.

CaroGen Corporation

Contact person: Bijan Almassian, President & CEO
Phone: 203 - 230 8596
Email: balmassian@carogencorp.com
Website: www.carogencorp.com
Technology from: Yale University

Company Overview
CaroGen is developing therapeutic vaccines (immunotherapies) for infectious diseases and cancer. CaroGen’s primary focus is on the development of a vaccine to treat patients with chronic hepatitis B virus (HBV) infection using its novel and transformative vaccine platform technology, which was discovered by Professor John Rose at Yale University. The platform is based on replicating nanoparticles dubbed replication-proficient virus-like vesicles (VLVs). These nanoparticles possess the ability to induce a high level of virus-specific T-cells that can eradicate liver cells infected with the HBV virus. The data supporting the proof-of-concept animal studies of CaroGen’s therapeutic vaccine for HBV was published in the August online issue of the Journal of Virology (http://www.ncbi.nlm.nih.gov/pubmed/26246574).
Chestnut Pharmaceuticals Inc.

Contact person: Taran Gujral, President
Phone: 617-417 7278
Email: taran@chestnutpharma.com
Technology from: Harvard Medical School

Company Overview
Chestnut Pharmaceuticals Inc. is an innovative biopharmaceutical company focused on developing targeted therapeutics paired with companion diagnostics for the treatment of advanced stage cancers. Metastasis (the spreading of cancer to distant organs) is responsible for the majority (>90%) of cancer deaths, yet there are no approved drugs designed specifically to address this need. Chestnut Pharmaceutical’s management team and scientific advisors are leaders in their respective fields, focused on research, development and commercialization of oncology-targeted drugs. Our founding team from Harvard Medical School possesses decades of in-depth mechanistic understanding of cancer metastasis and underlying biology, comprehensive knowledge of biomarker-based targeted drug development in oncology, and a history of proven success in oncology start-ups and life science research. Our lead product is a monoclonal antibody against Frizzled2 receptor (CP001) which directly targets ability of tumor cells to spread. The Company’s goal is for CP001 to be used in the treatment of several solid tumors in combination with standard-of-care therapy to prevent or delay metastasis, providing a multi-billion dollar revenue opportunity while serving life-threatening unmet medical needs.

Constant Therapy, Inc.

Contact person: Keith W. Cooper, CEO
Phone: 617-803-3354
Email: keith.cooper@constanttherapy.com
Website: www.constanttherapy.com
Twitter Handle: https://twitter.com/ConstantTherapy
Technology from: Boston University

Company Overview
Constant Therapy is a cloud based mobile solution that helps people improve their brain function & learning after a brain injury, stroke, or diagnosis of learning disorders or dementia. This is achieved with science-based exercises and with data analytics to automatically personalize exercise programs to each individual's needs. A recent study in Frontiers in Human Neuroscience showed that patients using Constant Therapy at home improved significantly and received 6x the amount of therapy compared to patients who only received therapy in-clinic. Constant Therapy has already served 12 million exercises via its mobile solution and is used by clinicians in hundreds of institutions, including Mass General Hospital and Kaiser Permanente.
Corsair Innovations
Contact person: William Lyndon, President
Phone: 781-223-6269
Email: wlyndon@gmail.com
Website: www.CorsairInnovations.com
Twitter Handle: @CorsairInnovate
Technology from: University of Massachusetts Dartmouth

Company Overview
Imagine a near future where the risk of Traumatic Brain Injury for our kids and teenagers is dramatically reduced. Corsair Innovations seeks to be the world’s leading provider of advanced protective materials for sports, military and safety applications. Flocked (Fibrous) Energy Absorbing Material (FEAM), a textile-based technology, uses a flocking process to attach thousands of upright short and stiff textile filaments (“flock”) onto both sides of a textile substrate. This radically improved impact energy absorbing (IEA) material effectively reduces Traumatic Brain Injury (concussions, etc.) and other injuries from direct and rotational hits.

CryptoMedix, LLC
Contact person: Janet Yancey-Wrona, COO
Phone: 207-317-0960
Email: jwrona@maine.rr.com
Technology from: University Southern California, Maine Medical Center Research Institute

Company Overview
CryptoMedix LLC (CMx) is an early stage biotechnology company, dedicated to the development of a new generation of ‘first-in-class’ therapeutic antibodies for treating cancer and inflammatory diseases. CMx technology is based on the discoveries of multi-pronged interactions between cryptic epitopes of collagen, that are exposed during disease, and key protumorigenic events, that occur in the tumor microenvironment, including interactions with immune-checkpoints that camouflage tumors from the immune system. These discoveries originate from Dr. Peter Brooks, Maine Medical Center Research Institute, CMx founder and Chief Scientific Advisor. The company has developed a platform of several mAbs against protumorigenic key epitopes of collagen, with compelling anti-tumor activities in vivo, and synergies with a variety of anti-cancer drugs, including immune-checkpoint inhibitors. These mAbs have shown anti-cancer activity in a variety of tumor types.

The company has secured exclusive worldwide licenses to 4 issued patents and 2 pending patents that cover the composition and use of its core antibodies.
Felsuma LLC
Contact person: Rana Gupta, CEO
Phone: 617-306 8280
Email: rana.gupta@felsuma.com
Technology from: UMass Amherst

Company Overview
Felsuma LLC has licensed a materials technology out of the University of Massachusetts Amherst that was developed to mimic a Gecko. The same way the Gecko can attach itself to a surface for long periods and then remove itself without leaving a trace and with very little force, Felsuma’s product is changing the way industries such as construction, consumer projects, apparel, industrial equipment and aerospace products attach to and release from other products/surfaces. Felsuma’s product can be custom designed based on customer needs. Manufacturing can be done on existing global roll-to-roll converting equipment. Raw materials are sourced from large global manufacturers. Felsuma is currently pursuing a B2B model and a secondary B2C model.

LayerBio, Inc.
Contact person: Aleksandr White, Vice President
Phone: 617-905-2544
Email: aleks@layerbio.com
Website: www.layerbio.com
Technology from: Massachusetts Institute of Technology

Company Overview
LayerBio is an early-stage biotechnology company commercializing novel drug delivery technology to enable life-changing therapies to patients in ophthalmology, wound care and orthopedics. Our LayerForm™ technology platform is based on a versatile biomaterials nanofabrication process developed in the laboratory of our co-founder, Dr. Paula Hammond, at Massachusetts Institute of Technology (MIT). Since its inception, LayerBio has raised $1.1 million in non-dilutive funding through multiple federal and state grants, industry collaborations and convertible debt. We are seeking our first round of angel funding to advance development of our lead product for glaucoma (LB-01) and expand our platform for additional therapeutic applications.
MazeFire LLC
Contact person: Donald M. O’Malley, Co-Founder
Phone: 781-707 8578
Email: d.omalley@neu.edu
Website: www.mazefire.com
Twitter Handle: @mazefire56
Technology from: Northeastern University

Company Overview

MazeFire games make learning fun. They also hit a sweet spot at the nexus of course work and game-based learning, a nexus that might produce the next EdTech killer app. Indeed, we believe that our patented Digital Maze games, which leverage student motivation and knowledge constructs, will soon be everywhere—from K12 to the Bar exam. Our present focus is on the College Freshman year and our organization embodies two abiding principles, namely: (1) Academic Reliability and (2) Easy Access. We consult with experts to ensure that our games meet the highest academic standards, while our market advantage (monopoly over two important game domains) adds flexibility to how we price and sell games. This means that a majority of our Semester Paks can be open access (click-and-play), making the entire world better in STEM, academic and general knowledge domains. MazeFire is a Northeastern University spin-out, led by Digital Maze inventor, neurobiology professor, and Synaptic Learning Theory proponent, Donald M. O’Malley. MazeFire has partnered with Orion Business Solutions and now has enterprise-grade educational/game software running on scalable AWS systems. But the bottom line, and there is no way to get around this, is that MazeFire Games make every learning venue better.

Mellitus, LLC
Contact person: Joyce Lonergan, CEO and Co-founder
Phone: 617-758 4146
Email: jlonergan@mellitusllc.com
Website: www.mellitusllc.com
Technology from: Harvard University

Company Overview

Mellitus was founded to develop and commercialize improved diagnostic tools for diabetes diagnosis and management, based on the research of Dr. Jose Halperin and Dr. Michael Chorev at Harvard. Diabetes is a disease of complications. Mellitus’ core technology is based on the identification of a novel, pathogenically-relevant biomarker, Glycated CD59 (GCD59), which is linked to the complications of diabetes. This link makes the measurement of GCD59 relevant for the screening, diagnosis, monitoring and measurement of complications risk in diabetes. Mellitus is developing an in vitro diagnostic test to measure GCD59 levels in blood. The first generation GCD59 Test is a standard immunoassay. This test format is applicable to next generation test platforms including automated testing systems and point of care technology. Mellitus has developed the tools to support next generation testing platforms.
NeuroFieldz Inc.
Contact person: Srinivas Sridhar, Director
Phone: 617-755 3838
Email: neurofieldz.info@gmail.com
Website: www.neurofieldz.com
Technology from: Northeastern University

Company Overview
NeuroFieldz aims to become a leader in the rapidly growing area of wearable brain monitoring applied to human performance, well-being and mental health. The central vision of NeuroFieldz is to develop cyber-integrated products for brain signal monitoring and analysis that will lead to greater quantitative information on brain activity, with portability and ease of use for a wide range of applications from clinical and laboratory neuroscience and neurology to military and consumer applications. The advantages of NeuroFieldz technology will have significant impact on detecting a wide range of neurological conditions including epilepsy and traumatic brain injury as well as in brain computer interfaces (BCI), human performance assessment and neurofeedback.

PanTher Therapeutics
Contact person: Laura Indolfi, Co-Founder and CEO
Phone: 857-413 1698
Email: lindolfi@panthertx.com
Website: www.panthertx.com
Twitter Handle: @panthertx - @lauraindolfi
Technology from: Massachusetts Institute of Technology – Massachusetts General Hospital

Company Overview
PanTher Therapeutics is leveraging targeted drug delivery and existing clinical paradigms for structural support to provide superior localized cancer therapies. With both a matrix and stent in development, PanTher is a platform technology with potential applications for pancreatic cancer as well as colorectal, esophageal, and mesothelioma. PanTher's technology enhances therapeutic efficacy 12x the current standard of care by delivering a higher payload of drug directly to the tumor mass, drastically reducing tumor growth and metastasis. PanTher’s value proposition includes a reduction of overall healthcare costs by increasing the number of curable patients and minimizing repeated procedures.
SLIPS Technologies, Inc.

Contact person: Daniel Behr, CEO
Phone: 781-258 6230
Email: Daniel@slipstechnologies.com
Website: www.slipstechnologies.com
Twitter Handle: @slipstech
Technology from: Harvard University

Company Overview
SLIPS Technologies, Inc. is the leader in solving sticky surface problems for industrial, medical, and consumer applications. We make SLIPS™, a family of materials and coatings with fully-slippery surfaces that repel virtually all fluids and biological fouling agents. The company started operations in Oct 2015 and licensed a 30+ patent portfolio from Harvard (plus our own filings since then). Our first year accomplishments include: 400+ customer interactions (most of them inbound!), 30 paid evaluations, multiple customer success stories, 4 paid product development programs, and $575K in grant funding. We currently have 11 full-time people working out of our labs in Cambridge, including CTO Phil Kim, one of the inventors of SLIPS, and two experienced business development professionals. The team is led by CEO Daniel Behr who brings 25 years of experience in dozens of startups as serial entrepreneur, venture investor and technology transfer professional.

Sonation, Inc.

Contact person: Ann Chao, CEO & Cofounder
Phone: 201-887 8828
Email: ann@sonation.net
Website: www.sonacadenza.com
Twitter Handle: @sonacadenza
Technology from: UMass Amherst

Company Overview
Sonation makes music more fun for the 600M+ people around the world who sing and play instruments, through our interactive music apps. Our vision is to become the “iTunes” for interactive music.

Sonation’s technology transforms static audio recordings into interactive tracks that listen and adapt to the user’s tempo. Our first product, Cadenza, helps students learning instruments practice with their own personal orchestra.
Standard Molecular, Inc.
Contact person: Nathaniel Weiss, CEO
Phone: 617-401-3318
Email: nathaniel@standardmolecular.com
Website: www.standardmolecular.com
Technology from: Memorial Sloan Kettering

Company Overview
Standard Molecular is a molecular pathology solutions company that enables hospitals to deliver leading edge diagnosis and treatment based on a patient’s DNA. Most hospital labs are not designed to manage next-generation sequencing (NGS) platforms and the associated workflow, regulatory requirements or the unprecedented amount of data. Standard Molecular offers software that enables hospitals to adopt NGS, manage the complex workflow, and provide leading-edge diagnosis and treatment.

Standard Molecular’s core technology was licensed from Memorial Sloan Kettering (MSK), and has secured its first customer and initial financing from an experienced healthcare IT fund. The Company has also formed a development partnership with a leading sequencing company. The Company is raising capital to build out its Genomic Information System (GIS).

StreetScan Inc.
Contact person: Ralf Birken, COO & CTO
Phone: 617-515 1995
Email: ralf.birken@streetscan.com
Website: www.streetscan.com
Twitter Handle: @streetscaninc
Technology from: Northeastern University

Company Overview
StreetScan is addressing the significant problem of aging civil infrastructure facing our society. More than 1.3M miles of US roads are in poor or mediocre conditions. Municipalities allocate their limited maintenance budgets based on subjective outdated pavement condition surveys failing to achieve maximum impact. Municipalities need automated inspection tools that are objective, effective, repeatable, and affordable combined with guidance on how to best allocate their pavement repair funding.

StreetScan provides a pavement inspection and management service that is fast, objective, and affordable to be used city-wide on a frequent basis, ensuring that repair decisions are never based on outdated or incomplete data. There are three parts to our core technology: an Innovative Mobile Sensing Solution, Big Data Handling and Analysis, and deliverables in a Web-based GIS Application.
**VitaThreads, LLC**  
**Contact person:** Adam Collette, President & CEO  
**Phone:** 508-762-1520  
**Email:** acollette@vitathreads.us  
**Website:** www.vitathreads.us  
**Technology from:** Worcester Polytechnic Institute  

**Company Overview**  
VitaThreads is dedicated to providing patients with superior skin wound closure using their unique VitaSuture absorbable suture technology. VitaThreads will address a 10% adverse event rate associated with use of current suture materials. The VitaSuture Wound Management System leverages VitaThreads unique suture which has been designed to more closely approximate soft tissue mechanics while absorbing more quickly than currently existing absorbable sutures. This minimizes the degree of suture-generated insult to healing tissue and its duration eliminating key causal factors for suture-linked adverse events.

---

**Weave Visual Analytics, Inc**  
**Contact person:** Howard Berke, President & CEO  
**Phone:** 978-996-3121  
**Email:** howard.berke@iweave.com  
**Technology from:** UMass Lowell  

**Company Overview**  
Weave Visual Analytics, Inc. (WVAi) is a spinoff from UMass Lowell and Prof. Georges Grinstein’s Institute for Visualization and Perception Research. The company is developing a next generation open source business intelligence platform and support services to provide customers with seamless data interoperability and timely decision-making. The software platform incorporates 20 years of prior research and 150+ person-years of development which was externally funded by $5M-$6M in grants. Weave will transform traditional business intelligence from reactive to proactive, predictive decision-making. Weave software can be tightly integrated into broad-based data infrastructure and has the capability to access any type of data. By channeling data through WeaveNexus™ and linking to other applications, the user can capture analytical insights and turn them into operational decision support.
Thank you to our Supporters